4-甲基-1,8-萘啶 | 1569-17-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4-甲基-1,8-萘啶
• 英文名称: 4-methyl-1,8-naphthyridine
• 英文别名: 4-Methyl-[1,8]naphthyridin
• CAS: 1569-17-1
• 化学式: C₉H₈N₂
• mdl: MFCD00234525
• 分子量: 144.176
• InChiKey: GARZCKWHNSKEPP-UHFFFAOYSA-N

物化性质

• 沸点：
  271℃
• 密度：
  1.141
• 闪点：
  116℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-甲基-1,8-萘啶 在 selenium(IV) oxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 1.5h， 以77%的产率得到1,8-萘啶-4-甲醛
  参考文献：
  名称：

  Discovery of Azetidinyl Ketolides for the Treatment of Susceptible and Multidrug Resistant Community-Acquired Respiratory Tract Infections

  摘要：

  Respiratory tract bacterial strains are becoming increasingly resistant to currently marketed macrolide antibiotics. The current alternative telithromycin (1) from the newer ketolide class of macrolides addresses resistance but is hampered by serious safety concerns, hepatotoxicity in particular. We have discovered a novel series of azetidinyl ketolides that focus on mitigation of hepatotoxicity by minimizing hepatic turnover and time-dependent inactivation of CYP3A isoforms in the liver without compromising the potency and efficacy of 1.

  DOI：

  10.1021/jm900729s
• 作为产物：
  描述：

  4-甲基-1,8-二氢-1,8-二氮杂萘-2,7-二酮 在 氢氧化钾 、 钯 、 三氯氧磷 作用下， 生成 4-甲基-1,8-萘啶
  参考文献：
  名称：

  Miyaki, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1942, vol. 62, p. 26,35

  摘要：

  DOI：

文献信息

• HIGHLY-FLUORESCENT AND PHOTO-STABLE CHROMOPHORES FOR ENHANCED SOLAR HARVESTING EFFICIENCY
  申请人：NITTO DENKO CORPORATION

  公开号：US20130074927A1

  公开（公告）日：2013-03-28

  The invention provides highly fluorescent materials comprising a single (n=0) or a series (n=1, 2, etc.) of benzo heterocyclic systems. The photo-stable highly luminescent chromophores are useful in various applications, including in wavelength conversion films. Wavelength conversion films have the potential to significantly enhance the solar harvesting efficiency of photovoltaic or solar cell devices.

  这项发明提供了包括单个（n=0）或一系列（n=1、2等）苯并杂环系统的高荧光材料。这种光稳定的高发光色团在各种应用中很有用，包括波长转换膜。波长转换膜有潜力显著提高光伏或太阳能电池器件的太阳能收集效率。
• 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF
  申请人：Bennett Frank

  公开号：US20100322901A1

  公开（公告）日：2010-12-23

  The present invention relates to 5,6-ring annulated indole derivatives of the formula (I), compositions comprising at least one 5,6-ring annulated indole derivatives, and methods of using the 5,6-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

  本发明涉及公式（I）的5,6-环接合吲哚衍生物，包含至少一种5,6-环接合吲哚衍生物的组合物，以及利用这些5,6-环接合吲哚衍生物治疗或预防患者病毒感染或与病毒相关的疾病的方法。
• Identification of 1,5-Naphthyridine Derivatives as a Novel Series of Potent and Selective TGF-β Type I Receptor Inhibitors
  作者：Françoise Gellibert、James Woolven、Marie-Hélène Fouchet、Neil Mathews、Helen Goodland、Victoria Lovegrove、Alain Laroze、Van-Loc Nguyen、Stéphane Sautet、Ruolan Wang、Cheryl Janson、Ward Smith、Gaël Krysa、Valérie Boullay、Anne-Charlotte de Gouville、Stéphane Huet、David Hartley

  DOI：10.1021/jm0400247

  日期：2004.8.1

  Optimization of the screening hit 1 led to the identification of novel 1,5-naphthyridine aminothiazole and pyrazole derivatives, which are potent and selective inhibitors of the transforming growth factor-beta type I receptor, ALK5. Compounds 15 and 19, which inhibited ALK5 autophosphorylation with IC50 = 6 and 4 nM, respectively, showed potent activities in both binding and cellular assays and exhibited

  筛选命中1的优化导致鉴定了新型1,5-萘啶氨基噻唑和吡唑衍生物，它们是转化生长因子βI型受体ALK5的有效抑制剂。分别以IC50 = 6和4 nM抑制ALK5自磷酸化的化合物15和19在结合和细胞分析中均显示出强大的活性，并显示出超过p38促分裂原活化蛋白激酶的选择性。描述了与人ALK5结合的19的X射线晶体结构，证实了对接研究提出的结合模式。
• NOVEL FAP INHIBITORS
  申请人：UNIVERSITEIT ANTWERPEN

  公开号：US20140357650A1

  公开（公告）日：2014-12-04

  The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.

  本发明涉及具有高选择性和特异性的新型抑制剂，用于FAP（成纤维细胞激活蛋白）。所述抑制剂可用作人类和/或兽医药物，特别用于治疗和/或预防与FAP相关的疾病，如但不限于增殖性疾病。
• [EN] PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS<br/>[FR] INHIBITEURS PTÉRIDINE DIONE DU TRANSPORTEUR DE MONOCARBOXYLATE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2016118823A1

  公开（公告）日：2016-07-28

  The invention provides compounds effective as inhibitors of monocarboxylate transporters such as MCT1 and MCT4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor effect on MCT1, MCT4, or both is medically indicated. Compounds of the invention can have antitumor, antidiabetes, anti-inflammatory, or immunosuppressive pharmacological effects, and can be effective for treatment of cancer and of type II diabetes.

  本发明提供了有效作为单羧酸转运蛋白如MCT1和MCT4抑制剂的化合物，这些化合物可用于治疗医学状况，其中使用对MCT1、MCT4或两者具有抑制作用的化合物治疗该状况在医学上是适宜的。本发明的化合物可能具有抗肿瘤、抗糖尿病、抗炎或免疫抑制的药理作用，并且可有效治疗癌症和II型糖尿病。

表征谱图